Molecular aspects of multiple myeloma

Annals of Oncology

Volumn 11, Issue 10, 2000, Pages 1217-1228

  Kastrinakis, N G ^a   Gorgoulis, V G ^a   Foukas, P G ^a   Dimopoulos, M A ^a   Kittas, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cell cycle; Cytogenetics; Human herpesvirus 8; Interleukin 6; Multiple myeloma; Therapy

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); FAS ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PROTEIN BCL 2;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CHROMOSOME TRANSLOCATION; CYTOGENETICS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; HUMAN HERPESVIRUS 8; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0033758812     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008331714186     Document Type: Review

References (187)

1. Plasma cell myeloma - New biological insights and advances in therapy
2. Variation in survival of adult patients with haematological malignancies in Europe since 1978
3. Monoclonal gammopathies of undertermined significance
4. 'Benign' monoclonal gammopathy-after 20-35 years of follow-up
5. The clonogenic precursor cell in multiple myeloma
6. A new staging system for multiple myeloma based on the number of S-phase plasma cells
7. The role of adhesion molecules in multiple myeloma
8. Multiple myeloma: New aspects of biology and treatment
9. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
10. Update of gp130 cytokines in multiple myeloma
11. Growth control mechanisms in multiple myeloma
12. STAT3 is required for the gp130-mediated full activation of the c-myc gene
13. Molecular analysis of multiple myeloma cells
14. Cellular resistance mechanisms with impact to therapy of multiple myeloma
15. 14q32 Translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome
16. IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc
17. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
18. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences
19. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
20. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
21. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogenic transplantation of hematopoietic cells
22. Homing mechanisms of myeloma cells
23. Biological significance of heterogeneity in human myeloma cells
24. The role of adhesion molecules in multiple myeloma
25. Homing behaviour of the malignant cell clone in multiple myeloma
26. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin
27. Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts
28. New bisphosphonates in the treatment of bone disease
29. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma
30. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy
31. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoclasts: A possible role for HGF in myeloma-associated osteolytic bone disease
32. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma
33. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma
34. Long-term parmitronate treatment of advanced multiple myeloma patients reduces skeletal events
35. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
36. CD138/syndecan-1: A useful immunohistochemical marker of normal and neoplastic plasma cells routine trephine bone marrow biopsies
37. Elevated levels of shed syndecan-1 correlate strongly with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma
38. Serum syndecan-1: A new independent prognostic marker in multiple myeloma
39. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth and bone cell differentiation
40. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9
41. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease
42. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 estblished from patients with advanced stage of the disease
43. Expression of ras oncogenes in cultured human cells alters the tranciptional and post-trancriptional regulation of cytokine genes
44. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6
45. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias
46. Interleukin-6 family of cytokines and gp130
47. Oncostatin M, leukemia inhibitory factor and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer gp130
48. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
49. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells
50. Upregulation of IL-6 receptors by IL-3 on a plasma cell leukemia cell line which proliferates dependently on both IL-3 and IL-6
51. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines
52. Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1β osteoclast activating factor-induced bone resorption
53. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma
54. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp130
55. Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma
56. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase
57. Association and activation of Jak-Tyk kinases by CNTF-LIF OSM-IL-6 beta receptor components
58. Interferon-beta interrupts interleukin-6-dependent signalling events in myeloma cells
59. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors
60. The Jak-STAT pathway: Cytokine signalling from the receptor to the nucleus
61. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis
62. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
63. IFN-α induces autocrine production of IL-6 in myeloma cell lines
64. γ-Interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro
65. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6
66. Cytogenetic study in multiple myeloma
67. Plasma cell karyotype in multiple myeloma
68. Karyotype in multiple myeloma and plasma cell leukemia
69. Cytogenetic findings in 200 patients with multiple myeloma
70. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations
71. Prognostic value of cytogenetics in multiple myeloma
72. Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype
73. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis
74. The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus
75. Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization
76. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization
77. Refinement of the BCL-2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets
78. Isolation and characterisation of recombination events involving immunoglobulin heavy chain switch regions in multiple myeloma using long distance vectorette PCR (LDV-PCR)
79. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines
80. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies
81. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization
82. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
83. Molecular analysis of 11q13 breakpoints in multiple myeloma
84. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
85. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell
86. An additional breakpoint region in the BCL-1 locus associated with the t(11;14)(q13;q32) translocation of B-lymphocytic malignancy
87. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma
88. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32)
89. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
90. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization
91. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth factor receptor 3 gene
92. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
93. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines
94. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma
95. Burkitt's type translocation in multiple myeloma
96. Der(16)t(1;16)(q10;p10) in multiple myeloma: A new non-random abnormality that is frequently associated with Burkitt's-type translocations
97. A variant Burkitt-type translocation (8;22)(q24;q11) in multiple myeloma. Report of a new case and review of the literature
98. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
99. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene
100. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping
101. BCL-3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders
102. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization
103. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome
104. Plasmablastic morphology: An independent prognostic factor with clinical and laboratory correlates. Eastern Cooperative Oncology Group (ECOG)
105. Myeloma cells release soluble interleukin-6Rα in relation to disease progression by two distinct mechanisms: Alternative splicing and proetolytic cleavage
106. Human myeloma cells shed the interleukin-6 receptor: Inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor
107. Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells
108. Expression of BCL-2 family of proteins in fresh myeloma cells
109. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance
110. BCL-2 expression in plasma cells from neoplastic gammoopathies and reactive plasmacytosis: A comparative study
111. Frequent hypermethylation of p16 and p15 genes in multiple myeloma
112. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
113. Characterization of p16 (INK4A) expression in multiple myeloma and plasma cell leukemia
114. Analysis of the p16(INK4A), p15(INK4B) and p18(INK4C) genes in multiple myeloma
115. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis
116. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
117. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells
118. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells
119. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: An in situ analysis
120. Expression of c-myc p62 oncoprotein in multiple myeloma: An immunohistochemical study of 180 cases
121. Mutations in the coding region of c-myc occur independently of mutations in the regulatory regions and are predominantly associated with myc/Ig translocation
122. Investigation of aberrant translational control of c-myc in cell lines derived from patients with multiple myeloma
123. A single nucleotide change in the c-myc internal ribosome entry segment leads to enhanced binding of a group of protein factors
124. p53 and ras gene mutations in multiple myeloma
125. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias
126. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group phase III trial
127. Oncogenic and transcriptional cooperation with Ha-ras requires phosphorylation of c-Jun on serines 63 and 73
128. JNK1: A protein kinase stimulated by UV light and Ha-ras that binds and phosphorylates the c-Jun activation domain
129. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively
130. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: Correlation with cyclin-D1 immunoreactivity
131. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma
132. Expression of Apo-1/Fas (CD95), BCL-2, Bax and BCL-x in myeloma cell lines: Relationship between responsiveness to anti-Fas mab and p53 functional status
133. Mutations in the Fas antigen in patients with multiple myeloma
134. The retinoblastoma susceptibility protein gene RB-1 in multiple myeloma
135. N-ras and p53 gene mutations are very rare events in multiple myeloma
136. p53 gene mutations in multiple myeloma
137. p53 gene mutations are rare in patients but common in patient-originating cell lines in multipole myeloma
138. Mutations of the p53 gene in human myeloma cell lines
139. Over-expression of the MDM2 gene is found in some cases of haematologic malignancies
140. MDM2 protein over-expression promotes proliferation and survival of multiple myeloma cells
141. Resistance to the chemosensitizer verapamil in a multidrug-resistant (MDR) human multiple myeloma cell line
142. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells
143. Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells
144. Deletion of a consensus oestrogen response element half-site in the glucocorticoid receptor of human multiple myeloma
145. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
146. PTEN gene alterations in lymphoid neoplasms
147. Cell death induced by the Fas/Fas ligand pathway and its role in pathology
148. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
149. Matrix metalloproteinases
150. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation
151. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
152. Serum metalloproteinases and their inhibitors: Markers for malignant potential
153. Antitumor activity of thalidomide in refractory multiple myeloma
154. Therapy with thalidomide in refractory multiple myeloma patients - The revival of an old drug
155. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex
156. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6
157. Molecular mechanisms of multidrug resistance in cancer chemotherapy
158. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6
159. New members of the BCL-2 family and their protein partners
160. Differential expression of BCL-2 in human plasma cell disorders according to proliferation status and malignancy
161. BCL-2 expression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells
162. Decreased CP-(NF-Y) activity results in transcriptional down-regulation of topoisomerase II-α in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226
163. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1)
164. Evidence for a p23 caspase-cleaved form of p27[KIP1] involved in G1 growth arrest
165. p53, The cellular gatekeeper for growth and division
166. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation
167. Identification of herpes-virus-like DNA sequences in AIDS-associated Kaposi's sarcoma
168. KSHV and Kaposi's sarcoma: The end of the beginning?
169. Kaposi's sarcoma-associated herpes virus-like DNA sequences are present in AIDS-related body cavity B-cell lymphomas
170. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease
171. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpes-virus 8: Determinants of its patogenicity?
172. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma
173. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
174. Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
175. Low incidence of human herpesvirus 8 in stem-cell collections from myeloma patients
176. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) DNA sequences are absent in leukapheresis products and ex vivo expanded CD34+ cells from multiple myeloma patients
177. HHV-8 in multiple myeloma: Is this the first paracrine model of human tumorigenesis and do Koch's postulates apply?
178. Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma
179. HHV-8 infection and multiple myeloma
180. Molecular and serological examination of the relationship of human herpes-virus 8 to multiple myeloma: Orf 26 sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected
181. Multiple myeloma and HHV-8 infection
182. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells
183. PCR with degenerate primers for highly conserved DNA polymerasegene of the herpesvirus family shows neither herpesvirus 8 nor a related variant in bone marrow stromal cells for multiple myeloma patients
184. Novel approaches in myeloma therapy
185. DNA vaccination against multiple myeloma
186. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma